Press Room | PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.
Press Conference

Recent Media Coverage

Read recent articles about PerkinElmer below. Clicking a headline will take you to the publication’s website for the full article.

Saliva Test Developed in NYC Makes COVID Tests Less Invasive

Mount Sinai Health System is making COVID-19 testing less invasive and more efficient for local schools, businesses and other organizations. FOX 5 recently took a look inside the lab, which also features several PerkinElmer instruments.

Improved Sensitivity and Multiplexing in COVID-19 Diagnostic Assays

Arvind Kothandaraman, managing director of specialty diagnostics at PerkinElmer, shares the concept and benefits of pooling tests while describing PerkinElmer’s PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel Assay, and his take on the outlook of COVID-19 diagnostics.

New Tool to Help Speed Up Life-Saving Drug Treatments

PerkinElmer’s automated explorer™ G3 workstation and Opera Phenix HCS technologies will help the University of Colorado’s Anschutz Medical Campus exponentially speed up its drug discovery work around diseases such as cancer, diabetes, cardiovascular disease and Alzheimer’s.

EUROIMMUN qualitative and semi-quantitative IgG test receives FDA EUA

Based on EUROIMMUN’s Anti-SARS-CoV-2 QuantiVac ELISA (IgG) that received CE mark in November 2020, the Anti-SARS-CoV-2 S1 Curve ELISA (IgG) has obtained EUA from the FDA. This assay allows for the qualitative and semi-quantitative detection of IgG antibodies formed against the SARS-CoV-2 S1 antigen.

PerkinElmer Receives FDA Emergency Use Authorization for Respiratory COVID-19 Panel

The FDA has granted EUA for PerkinElmer’s PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1 assay, which simultaneously detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV). This will alleviate confusion from similar symptoms amid a possible "twindemic" of COVID-19 and influenza.

40th Anniversary Recollections & Predictions

In this special issue of GEN, the magazine uncovers major milestones and predictions from thought leaders in biotechnology and life sciences. PerkinElmer’s Senior Vice President of Life Science Alan Fletcher and Associate Director of Scientific Affairs at EUROIMMUN, a PerkinElmer company, Iswariya Venkataraman, share their insights around personalized medicine and automated immunofluorescence microscopy.

Optimizing the Utilization of Lab Assets

Optimizing the usage of equipment and instruments is crucial for lab managers. PerkinElmer’s Carola Schmidt, global director of automated solutions, and Jim Sweeney, senior product manager, global services shared their thoughts on the management of lab assets as well as the metrics and measurement of lab efficiency.

ctDNA and Cancer: Diagnostics, Treatments, and Monitoring

Amar Kamath, VP and general manager of Diagnostics at PerkinElmer, and Aldo Mele, senior scientist 2 at Horizon Discovery, a PerkinElmer company, share insights on how circulating tumor DNA (ctDNA) can be a promising method of routine testing for cancer care.

Screening Saves Lives, So Why don’t Governments Fund it?

Funded by the American Society of Hematology, the Consortium on Newborn Screening in Africa (CONSA) aims to screen 10,000–16,000 babies per year over the next 5 years across Africa for sickle-cell disease. PerkinElmer is supporting the effort with donations and local training.

Top Women in Precision Medicine

Madhuri Hegde, senior vice president and chief scientific officer at PerkinElmer Genomics, is featured in Clinical OMICs’ annual selection of women making their mark in precision medicine. Dr. Hegde shares her life stories and experiences that have led to her success in the field.

Powering Diagnostics for Infectious Disease

According to industry experts, COVID-19 may have accelerated interest in next-generation sequencing (NGS). PerkinElmer Genomics SVP and Chief Scientific Officer Madhuri Hegde comments on advances in NGS technologies and its potential applications in infectious disease diagnostics.

BioLegend to Be Acquired for $5.25 Billion

PerkinElmer has agreed to acquire BioLegend, a global leader of antibodies and reagents. This will be the largest transaction in PerkinElmer’s history and expand PerkinElmer’s and extend their life science franchise into new segments.

What to Know About the Coronavirus Lambda Variant

As a “variant of interest” labeled by the WHO, the lambda variant has been circulating in multiple countries. Iswariya Venkataraman, PhD, associate director of scientific affairs at EUROIMMUN, a PerkinElmer company, talks about how new variants arise in communities.

Don’t Break My Strands

For cancer immunotherapy, multiple gene knockouts are required to augment the properties of the immune cell used for treatment. Emily M. Anderson, a principal scientist from Horizon Discovery, a PerkinElmer company, introduces how the DNA double-strand breaks (DSBs) could have an impact.

PerkinElmer’s Support Creates World’s Largest Public Cell Painting Dataset

PerkinElmer is providing its PhenoVue Cell Painting Kits to the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) consortium, which is led by the Broad Institute of MIT and Harvard and focused on creating and sharing the world’s largest, public cell imaging data set.

NIH Study Offers Evidence of Early SARS-CoV-2 Infections in the U.S.

PerkinElmer’s EUROIMMUN SARS-CoV-2 ELISA (IgG) is one of two antibody tests used by the NIH’s All of Us program, which recently published evidence of SARS-CoV-2 infections in five U.S. states earlier than had initially been reported.

PerkinElmer CEO Prahlad Singh Talks Business Transformation on CNBC’s Mad Money

Our President and CEO Prahlad Singh recently joined Jim Cramer on CNBC’s Mad Money to describe how agility and innovation continue to fuel PerkinElmer's transformation. In this interview, Prahlad talked about the Company's recent acquisitions and future opportunities in the Life Sciences and Diagnostics sectors.

Getting Ahead of the Mycotoxin Testing Curve

Mycotoxins pose many challenges for feed and grain suppliers at every stage from harvest to final production. Mark MacBeath, Food Safety Product leader, and Wes Shadow, Global Market manager of Grain, outline the best technologies to aid mycotoxin monitoring and detection.

Can Immune Cell-Based Therapies Become Mainstream in Oncology?

Can gene editing technology help transition cell-based therapies to solid tumors? Jonathan Frampton, a Corporate Development Partner on our Horizon Discovery team, looks at the potential evolution of this currently costly approach into mainstream treatment of cancer patients through the application of base editing.

The Importance of E. coli Detection Methods

E. coli O157 testing has gained more attention from food producers and processors as the demand grows rapidly. Nevin Perera, Research and Development Manager at PerkinElmer, shares his insights about the steps to take to ensure safe and efficient E. coli testing.

How to Orchestrate Your Drug Discovery Journey

Standardization and validation are foundations in the selection of appropriate technology, methods, reagents and consumables. Anis H Khimani, Senior Strategy and Market Segment Leader at PerkinElmer Life Sciences, discusses how to orchestrate these factors towards a holistic outcome.

Viral Evolution Insights Will Help Us Fight COVID-19

One takeaway from COVID-19 is that understanding the mechanisms of viral evolution can help track variants in real time. Arvind Kothandaraman, our general manager of specialty diagnostics, explains how new and emerging technologies have enabled scientists and research to identify and monitor SARS-CoV-2 mutations.

Evolving Analytical Technology Unravels Protein Characteristics

Anis H. Khimani, senior strategy and product portfolio leader for Life Sciences at PerkinElmer, talks about the innovations and challenges in advancing capabilities for protein analytics to ensure the rapid development of safe and effective biotherapeutics.

Lab Automation in a Post-COVID World: 5 Questions to Ask and Answer

Automation has helped many labs keep pace with new and increasing demands brought on by COVID-19. In this article, our Global Director of Automated Solutions Carola Schmidt shares advice on how to setup new technology initiatives for success.

Next-Generation Sequencing for SARS-CoV-2 Surveillance

Next-generation sequencing (NGS) plays a vital role in COVID-19 surveillance. Our General Manager of NGS Michelle Fraser shares her thoughts on the latest advances in NGS technology and the global effort to track the virus and its variants.

Best Practices in HPLC to UHPLC Method Transfer

As the demand for faster separations, better peak resolution and lower detection limits increases, more food, pharma and industrial labs are moving from high performance liquid chromatography (HPLC) to ultra-high-performance liquid chromatography (UHPLC). Jackie Trudell, Portfolio Marketing Manager Chromatography and Mass Spectrometry, discusses the benefits and key considerations in making the transition smoothly.

Cell Painting: A Vibrant Future for Phenotypic Drug Discovery

Cell painting allows new strategies for high-content screening (HCS) practitioners to identify new drug candidates and study mechanisms of action by taking advantage of both cellular imaging and machine learning. Alexander Schreiner, high content screening applications leader, and Martin Daffertshofer, high content screening software product manager from PerkinElmer, discuss how cell painting is helping drug discovery and the current technical limitations and challenges.

Base Editing: The Next Frontier in Genome Editing Technology

Jonathan Frampton, a Corporate Development Partner on our Horizon Discovery team talks about how base editing differs from traditional genome editing tools and the exciting advances it could help help bring about, especially in cell-based therapy discovery.

Automation Extends Its Reach in Drug Discovery

Lab automation is increasingly critical for typical discovery and basic life science workflows. PerkinElmer’s executive director for science and technology David Gosalvez walks us through the key challenge for labs to adapt to modern, efficient systems that maximize the potential of instruments, time, and people.

The Evolving Problem of Microplastics in a PPE Era

In part one of a two part microplastics series, Kathleen A. Young, Environmental Market Leader at PerkinElmer, shares her thoughts on how PPE has increasingly impacted our environment and the importance of standardization in detecting microplastics.

PerkinElmer, Insightful Science to Integrate Software with Cloud-Based Data

PerkinElmer announced its Signals informatics platform will integrate with software from Insightful Science to expand on existing capabilities in the biologics drug discovery space, which will reduce research cycle times and accelerate biologics and vaccine development.

The Future of COVID Testing

Prahlad Singh, President and CEO of PerkinElmer, sat down with This Week in Business on NECN to talk about the Company’s COVID-19 RT-PCR and antigen tests, and how he perceives the COVID-19 testing landscape to be as vaccines roll out.

Celebrating Women Empowerment

To commemorate International Women’s Day, Nicky Xu, General Manager of Diagnostics at PerkinElmer Greater China, shared how she led the development of the COVID-19 PCR test and organized national donations as a female leader.

Waltham Company Seeking FDA Approval for Rapid Test

Masoud Toloue, Senior Vice President of PerkinElmer Diagnostics, talked with 7News in Boston about PerkinElmer’s antigen test that detects SARS-CoV-2 nucleocapsid antigen in under 15 minutes. The test is expected to play an important role in point-of-care testing located at healthcare centers, travel hubs, businesses and schools.

Now on Base, Rutgers Team Reveals New Genome Editing Approach

Horizon Discovery, a PerkinElmer company, was licensed by Rutgers University for the modular base editing system that uses RNA aptamers to position DNA modifying enzymes at genome targets. This uses a pin-point system and can enhance the therapeutic potential of genome editing.

Choosing Reference Standards for Molecular Assay Development

Next-generation sequencing (NGS) is used to detect underlying molecular mechanisms and variants in multiple genes to achieve targeted treatment for cancer patients. Keith Cannon, Director of Commercial Product Management and Prabha Nagarajan, Senior Research Scientist at Horizon, a PerkinElmer company, highlight the importance and prospect of NGS initiatives.

PerkinElmer Launches its First Cell Painting Kit

As an addition to the PhenoVue cellular imaging reagent portfolio, PerkinElmer’s first cell painting kit completes the suite of high-content screening products and expert services to build more streamlined workflows.

The Impact of Emerging SARS-CoV-2 Variants on Diagnostic Testing

Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, discusses how the emerging genetic variants of SARS-Cov-2 can impact false negative rates and the characteristics RT-PCR assays need to remain accurate.

Proteomics Begins to Emerge from Genomics’ Shadow

John Rontree, Portfolio Director and Leader of Mass Spectrometry and Anis H. Khimani, senior strategy and market life sciences segment leader in life sciences at PerkinElmer share their thoughts on quantitation, automation and innovative assays in proteomics as an approach to understanding their role in complex biological systems, supporting high-throughput PCR testing environments and helping drive innovative therapeutics development for COVID-19.

Neutralizing Antibodies in the Fight against COVID-19

Since their discovery last year, coronavirus neutralizing antibodies have been touted as possible treatments and diagnostic targets. Anis H. Khimani, Senior Strategy and Market Segment Leader at PerkinElmer and Kai Fechner, Director of International Sales and Marketing at EUROIMMUN (a PerkinElmer company), talk about what defines an ideal NAb assay.

PerkinElmer E. coli Pathogen Detection for Beef & Beef Trim Testing

While most Escherichia coli strains are harmless, some can cause intestinal illness in groups under higher risk. PerkinElmer’s newly launched Solus One O157 Pathogen Detection Assay provides a highly sensitive, cost effective system with an industry-leading result sample volume.

Pandemic Pivot: How Scientists Answered the Call for Diagnostic Tests

As one of the world’s largest suppliers of laboratory and diagnostic reagents and equipment, PerkinElmer was in prime position to respond to COVID-19. As the pandemic took hold, Iswariya Venkataraman, scientific affairs manager at EUROIMMUN US, a PerkinElmer subsidiary, shares how the Company developed its now-established qualitative test to assist vaccine developers in understanding if their products elicited antibody responses, and how strong those responses were.

Vaccine innovation in the Age of COVID-19 & Beyond

Dr. Sanjay Garg, Operations of Sanofi Pasteur and our own Dr. Anis H. Khimani discuss how the COVID-19-driven innovation and collaboration cycles are changing vaccine development forever.

PerkinElmer to Acquire Oxford Immunotec for $591M

Through the acquisition of Oxford Immunotec, a leading company specialized in diagnosing infection with tuberculosis, PerkinElmer will grow its portfolio of advanced infectious disease testing solutions to include tuberculosis detection to better serve customers around the world.

Trendspotting: What’s Coming For Bio-IT In 2021

Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, talks about trends and predictions including additional forecasts for cross-biotech collaboration and the significance of digital technologies.

Overcoming Technical Challenges in Cannabis Analysis

Dr. Kaveh Kahen, Senior Director and General Manager of Mass Spectrometry at PerkinElmer, highlights technical challenges in cannabis testing and how they can help labs in this growing industry.

How COVID-19 Is Transforming Today's Labs

Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, shares his thoughts on how COVID-19 will continue to transform modern laboratories in 2021 and beyond.

PerkinElmer Named to WSJ’s Management Top 250

The Management Top 250 ranking measures corporate effectiveness by examining performance in five areas: customer satisfaction, employee engagement and development, innovation, social responsibility and financial strength.

30 Years of Developments in ICP-MS

This article takes a look back on the evolution of PerkinElmer’s ICP-MS innovations for environmental testing over the past three decades up through the new NexION 5000.

An Interview on Food Trends & Solutions

Our Head of Food, Greg Sears, talks with New Food about trends in food testing and quality, as well as how PerkinElmer’s solutions can help customers meet food and cannabis regulations.

Medical Companies Enjoy a Fruitful CIIE Outing

PerkinElmer hosted an exhibit at the Chinese International Import Expo (CIIE) where industry leaders could get an in-person look at our technologies including explorer™ workstations for SARS-CoV-2 testing.

Biobanks Are Becoming Data Banks in the Era of Personalized Medicine

Carola Schmidt, Global Director of Automated Solutions at PerkinElmer, shared her insight about biobanking and how to ensure the integrity and security to standardize the procedure and implement best practices.

The Need for Precise, Accurate, and Sensitive COVID-19 Tests

PerkinElmer JANUS G3 automated liquid handlers and chemagic 360 closed loop extraction unit have helped Synergy Diagnostic Laboratory in delivering COVID-19 tests to increase the capacity to more than 1,000 tests per shift.

SEMA4 – COVID-19 Viral and Antibody Testing

James Coffin, President and Chief Operating Officer, Sema4, talks about how PerkinElmer is providing best-in-class, highly accurate PCR tests (7:40 mark).

Compliance Services for Data Integrity

Gary Grecsek, Vice President/General Manager of Global OneSource Enterprise Laboratory Services and Tony Pezzolo, Product Manager of Validation, discuss how labs can stay in the know and ahead of the curve on compliance and data integrity challenges with the help of an external, expert compliance team.

PerkinElmer Launches Solus Listeria monocytogenes ELISA Assay

Listeria carries a 20 – 30% mortality rate for those in high-risk categories so vigilant testing is important. The PerkinElmer Solus Listeria monocytogenes ELISA Assay tests both food and environmental samples and has been certified by the AOAC.

It’s Time to Embrace Whole Genome Sequencing

Madhuri Hegde, Vice President and Chief Scientific Officer at PerkinElmer Genomics, shared how recent advancements in genomic sequencing technologies are enabling simultaneous rapid analysis for large amounts of genetic information, making it easier and faster to apply these learnings to clinical care.

Piracy in the Pantry

Stefan Tordenmalm, Market Manager of Processed Food at PerkinElmer, highlights the most common types of food fraud reported by customers and how analytical chemistry helps to ensure food safety and quality.

COVID-19 Antibody Testing: S vs. N Protein

Iswariya Venkataraman, Scientific Affairs Lead at EUROIMMUN, helped us demystify the differences between the S and N proteins, whose presence indicates the immune response against COVID-19.

New COVID-19 Environmental Surface Testing Kits from PerkinElmer

Though person-to-person transmission is the primary way of spreading COVID-19, environmental surfaces should also not be neglected. PerkinElmer’s environmental testing kits help detect the virus on surfaces such as plastic, ceramic, or stainless steel.

Hand Sanitizer Analyzer Detects Methanol in 30 Seconds or Less

With COVID-19 continuing to spread and flu season on the way, methanol recalls in hand sanitizers are unwelcomed news. Helping to ensure the safety of these high-demand products, PerkinElmer launched the enhanced Hand Sanitizer Analyzer providing methanol pass/fail results in 30 seconds starting at 300 ppm.

What to Consider When Choosing a SARS-CoV-2 Detection Assay

Arvind Kothandaraman, General Manager of Specialty Diagnostics at PerkinElmer, shares seven key factors that organizations should take into consideration when choosing a new COVID-19 testing workflow.

Open Access COVID-19 Data Dashboards to Accelerate Antiviral Therapeutics Research

As global scientists work tirelessly to discover therapeutics and vaccines for COVID-19, there’s massive amounts of existing data that can be invaluable. PerkinElmer has introduced open COVID-19 Data Dashboards to help scientists easily access, analyze and gain insights from data sources.

PerkinElmer, Inc. Launches AuroFlow® AQ Mycotoxin Platform

With the harvest season approaching, PerkinElmer is launching the AuroFlow® AQ Mycotoxin Platform to screen grain including corn and wheat. This new solution includes strip tests for various of mycotoxin contaminations.

7 Ways: Advancement in Science Could Impact Your Life

“FemTech” is a technology that addresses a variety of women’s health issues and according to Karen Madden, Ph.D., Vice President of Technology and Innovation at PerkinElmer, it is gaining more attention. She also shared insights into the Company's Vanadis non-invasive prenatal testing (NIPT) solutions.

Wales Gets National COVID-19 Testing Lab

PerkinElmer partners with Public Health Wales (PHW) to achieve the Welsh Government’s “Test, Trace, Protect” strategy by providing advanced extraction equipment and testing kits that meet the UK’s ongoing requirements.

How PerkinElmer is Helping Combat COVID-19

Amidst COVID-19, PerkinElmer is ready to support our global customers with a wide range of solutions, including detection, workflow and research.

The path to serology testing at Beaumont Health

EUROIMMUN Anti-SARS-CoV-2 ELISA testing kits are helping Beaumont Health as part of its research study demystify COVID-19 as the research expands to wider patient groups.

Identifying Food Fraud with Analytical Testing

Stefan Tordenmalm, Market Manager of Processed Food at PerkinElmer, shares his thoughts about the adulteration of olive oil, which is at high risk for food fraud. To ensure its quality, rapid testing techniques like infrared (IR) and UV-visible spectroscopy (UV-Vis) are crucial in protecting consumers./p>

PerkinElmer Expands Analysis and Automation Portfolio

Tailored for pharmaceutical, semiconductor, biomonitoring, food, materials and academia labs, PerkinElmer’s new analysis and automation solutions are designed to help streamline workflows, sharpen insights and meet regulations.

Quest Diagnostics Starts Antibody Testing for Coronavirus

To answer the need for wider COVID-19 testing in the US, EUROIMMUN, a PerkinElmer company, collaborates with Quest Diagnostics to detect immunoglobulin class G (IgG) antibodies. Quest is expected to boost testing to 150,000 a day by early May.

"Know your Career Aspirations and have a Clear Plan" #Women's Day 2020

Statistics show that women in China are more likely to be in senior leadership roles than many other Asian countries. Here Ms. Ye (Nicky) Xu, General Manager of Diagnostics at PerkinElmer Greater China shares her journey and some career, business and personal growth tips to help inspire the world’s women in science and healthcare.

Carcinogens Under the Scan

To ensure the safety of medicines, PerkinElmer offers pharma companies a comprehensive solution to detect N-nitrosodimethylamine (NDMA) impurity in ranitidine.